BIAF (bioAffinity Technologies) קצב צמיחת רווח למניה בשנה הנוכחית

Slow physician adoption of tests and marketing expenses previously constrained revenues for bioAffinity Technologies (BIAF). The volatility of annual earnings per share on the GURU.Markets chart currently reflects the present trend, where 0.00 indicates the level of this metric. Ahead lies the B2B expansion of the non-invasive CyPath Lung method, although patent disputes with tech startups will remain a key challenge.

This metric measures the year-over-year dynamics of earnings per share, reflecting the efficiency of capital generation. For bioAffinity Technologies (BIAF), this growth depends directly on the commercialization of patented cancer tests and their recognition by insurance companies. Analyzing the year-over-year change in EPS allows investors to distinguish a speculative asset from a fundamentally sustainable business, confirming the actual strength of the economic moat.